HC Wainwright & Co. Maintains Buy on IGM Biosciences, Lowers Price Target to $17
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Robert Burns maintains a 'Buy' rating on IGM Biosciences (NASDAQ:IGMS) but lowers the price target from $22 to $17.
August 07, 2023 | 4:21 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
IGM Biosciences' price target has been lowered from $22 to $17 by HC Wainwright & Co., though the 'Buy' rating is maintained.
The news directly pertains to IGM Biosciences as their price target has been lowered by HC Wainwright & Co. However, the 'Buy' rating is maintained which indicates that the analyst still sees potential in the stock. This could lead to mixed reactions in the market, hence the neutral score.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100